BioSpace News Archive

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2020 . Leap First Quarter Highlights: Entered into an exclusive option and license agreement with BeiGene, Ltd. for the clinic

Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, will present a poster at the 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place virtually from May 29-31. The ASCO poster, by Dr. Mohammed Milhem of the University of Iowa and coauthors, titled “AST-008: A Novel Approach to TLR

AVROBIO’s optimized lentiviral vectors demonstrate significant glycogen reduction in the muscle and central nervous system of Pompe disease mouse model Investigational New Drug (IND)-enabling proof-of-concept study for AVR-RD-03 for Pompe disease currently underway CAMBRIDGE, Mass.--( BUSINESS WIRE )-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease,

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2020 and provided a clinical and corporate update. “While the NODE-301 trial of et

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced that holders of its 11.5 million outstanding warrants will have until 5:00 p.m., New York City time, on June 15, 2020 to exercise their warrants. The 11.5 million warrants are exercisable for an aggregate of 5.75 million shares of Immunovant’s common stock at a price of $11.50 per share, r

Soliton, Inc., a medical device company with a novel and proprietary platform technology, reported financial results for the first quarter ended March 31, 2020.

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced first quarter 2020 financial results and provided an update on the cytisinicline clinical

Frequency Therapeutics Provides Business Updates and Reports First Quarter 2020 Financial Results Phase 2a Study of FX-322 for Sensorineural Hearing Loss Continues Enrollment at Multiple Sites Shares Top-Line Data from Exploratory Clinical Study Confirming Delivery of FX-322 to the Cochlea WOBURN, Mass.--( BUSINESS WIRE )-- Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s

Indivior PLC announced that its Q1 2020 press release is now available via the London Stock Exchange’s Regulatory News Service and on the “Investors” section of the company’s website at www.indivior.com.

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on HST 004, its patented, naturally-derived material for spinal disc repair in the Journal of Medicine and Surgical Sciences. Histogen has developed a cell conditioned media (CCM) that is embryonic-like in composition and that has been shown to stimulate stem cells in vivo. The ma